CrystecPharma
Paul Thorning is an accomplished executive with extensive experience in the pharmaceutical industry. As CEO of Crystec Pharma since September 2007, Paul has been instrumental in the company's growth and development. Currently, Paul serves as a Director at Inhalis Therapeutics SA, where a team is focused on advancing Inhalis101, a novel inhaled triple PI3K-mTOR-BRD4 inhibitor aimed at treating Idiopathic Pulmonary Fibrosis, Lung Cancer, and other fibrotic diseases. Paul has previously held leadership roles at the Institute of Pharmaceutical Innovation and CORD in Tanzania, as well as serving as Business and Market Research Director at AstraZeneca. Paul holds an MBA from Manchester Metropolitan University and a BSc in Mechanical Engineering from The University of Manchester.
This person is not in any teams
CrystecPharma
Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Applications of our mSAS® (modified Supercritical Anti-Solvent) technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics. Our solutions include the following: • Crystal and particle engineering • Stabilisation of therapeutic agents derived from biotechnology • Polymorph screening • Improved performance of poorly soluble drugs • Improved bioavailabilty of small molecules • Alternative routes of delivery such as inhaled therapy • Taste masking • Crystallisation seeds • Residual solvent elimination